Actively Recruiting
Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer
Led by Fujian Cancer Hospital · Updated on 2024-09-19
200
Participants Needed
1
Research Sites
116 weeks
Total Duration
On this page
Sponsors
F
Fujian Cancer Hospital
Lead Sponsor
F
Fujian Medical University Affiliated Nanping First Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Cadonilimab, a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the treatment of a range of solid tumors, including cervical cancer, lung cancer, gastric/gastroesophageal junction cancer, liver cancer and nasopharyngeal cancer. Cadonilimab was approved in China in June 2022 for use in patients with relapsed or metastatic cervical cancer who have progressed on or after platinum-based chemotherapy. The clinicopathological data of patients with persistent, recurrent or metastatic cervical cancer treated with Cadonilimab were collected, and medical images (magnetic resonance, CT, etc.) before and after treatment were followed up, and the efficacy was evaluated according to RECIST standards. The incidence and severity of adverse events and clinically significant abnormal laboratory test results were collected to evaluate the safety of the drug. Survival benefit analysis is conducted based on the patient's survival time and medical expenses.
CONDITIONS
Official Title
Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Persistent, recurrent or metastatic cervical cancer
- Pathological types include squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
- No other multiple primary cancers
- At least one measurable lesion by MRI or CT scan based on RECIST criteria
- ECOG performance status score of 0-1
- Provided informed consent and agreed to clinical follow-up
You will not qualify if you...
- Histopathological types other than squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma, such as small cell carcinoma, clear cell carcinoma, or sarcoma
- Previous treatment with immune checkpoint inhibitors
- Drug contraindications including liver or kidney function insufficiency
- Withdrawal of informed consent
- Investigator's decision that the patient is unsuitable for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
No. 420 Fuma Road, Jin'an District, Fuzhou City, Fujian Province
Fuzhou, Fujian, China, 350074
Actively Recruiting
Research Team
Y
Yang Sun, Master
CONTACT
J
Jian Chen
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here